The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

被引：2

作者：

Horwitz, Steven M. ^{[1
]}

O'Connor, Owen A. ^{[2
]}

Pro, Barbara ^{[3
]}

Illidge, Tim M. ^{[4
]}

Fanale, Michelle A. ^{[5
]}

Advani, Ranjana H. ^{[6
]}

Bartlett, Nancy L. ^{[7
]}

Christensen, Jacob Haaber ^{[8
]}

Morschhauser, Franck ^{[9
]}

Domingo-Domenech, Eva ^{[10
]}

Rossi, Giuseppe ^{[11
]}

Kim, Won Seog ^{[12
]}

Feldman, Tatyana A. ^{[13
]}

Lennard, Anne ^{[14
]}

Belada, David ^{[15
,16
]}

Illes, Arpad ^{[17
]}

Tobinai, Kensei ^{[18
]}

Tsukasaki, Kunihiro ^{[19
]}

Yeh, Su-Peng ^{[20
]}

Shustov, Andrei R. ^{[21
]}

Huettmann, Andreas ^{[22
]}

Savage, Kerry J. ^{[23
,24
]}

Yuen, Sam ^{[25
]}

Zinzani, Pier Luigi ^{[26
]}

Hua, Zhaowei ^{[27
]}

Little, Meredith ^{[27
]}

Rao, Shangbang ^{[28
]}

Woolery, Joseph ^{[28
]}

Manley, Thomas ^{[29
]}

Truemper, Lorenz ^{[30
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA

[4] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci,Fac Biol Med & Hlth,NIHR Biomed Res, Manchester, Lancs, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Stanford Canc Ctr, Blood & Marrow Transplant Program, Stanford, CA USA

[7] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[8] Odense Univ Hosp, Odense, Denmark

[9] CHRU Lille, Lille, Nord Pas De Cal, France

[10] Inst Catala Oncol, Barcelona, Spain

[11] Azienda Osped Spedali Civili Brescia, Brescia, Italy

[12] Samsung Med Ctr, Seoul, South Korea

[13] Hackensack Univ Med Ctr, Hackensack, NJ USA

[14] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[15] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[16] Charles Univ Prague, Fac Med, Prague, Czech Republic

[17] Debreceni Egyet, Debrecen, Hungary

[18] Natl Canc Ctr, Tokyo, Japan

[19] Saitama Med Univ, Dept Hematol, Int Med Ctr, Saitama, Japan

[20] China Med Univ Hosp, Taichung, Taiwan

[21] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[22] Univ Klinikum Essen, Essen, Germany

[23] Univ British Columbia, Vancouver, BC, Canada

[24] British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada

[25] Calvary Mater Newcastle Hosp, Newcastle, NSW, Australia

[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[27] Takeda Pharmaceut Int Co, Cambridge, MA USA

[28] Seattle Genet, Bothell, WA USA

[29] Seattle Genet Inc, Bothell, WA USA

[30] Univ Med Gottingen, Gottingen, Germany

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

997

引用

页数：5

共 50 条

[31] Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial
Svoboda, Jakub
Landsburg, Daniel J.
Nasta, Sunita Dwivedy
Barta, Stefan Klaus
Khan, Nadia
Fung, Henry C.
Tan, Carlyn Rose
Filicko-O'Hara, Joanne
Gaballa, Sameh
Strelec, Lauren Elizabeth
Nagle, Sarah J.
Bair, Steven M.
Mitnick, Sheryl
Waite, Terease S.
Sargent, Rachel Lynn
Bogusz, Agata M.
Sahin, Ziver
Mato, Anthony R.
Schuster, Stephen J.
BLOOD, 2017, 130
[32] Brentuximab Vedotin With R-CHP Chemotherapy as Frontline Treatment for Patients With CD30-Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial
Moskowitz, Craig H.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 9 - 10
[33] The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 4 - 6
[34] The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
Moskowitz, Craig H.
Nadamanee, Auayporn
Masszi, Tamas
Agura, Edward
Holowiecki, Jerzy
Abidi, Muneer H.
Chen, Andy I.
Stiff, Patrick J.
Gianni, Alessandro M.
Carella, Angelo M.
Osmanov, Dzhelil
Bachanova, Veronika
Sweetenham, John
Sureda, Anna
Huebner, Dirk
Larsen, Emily K.
Hunder, Naomi N. H.
Walewski, Jan
BLOOD, 2014, 124 (21)
[35] The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
Moskowitz, Craig H.
Nadamanee, Auayporn
Masszi, Tamas
Agura, Edward
Holowiecki, Jerzy
Abidi, Muneer H.
Chen, Andy
Stiff, Patrick J.
Gianni, Alessandro M.
Carella, Angelo M.
Osmanov, Dzhelil
Bachanova, Veronika
Sweetenham, John
Sureda, Anna
Huebner, Dirk
Larsen, Emily K.
Hunder, Naomi N. H.
Walewski, Jan
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S28 - S28
[36] Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas
Herrera, Alex F.
Zain, Jasmine
Savage, Kerry J.
Feldman, Tatyana A.
Brammer, Jonathan E.
Chen, Lu
Popplewell, Leslie L.
Budde, Lihua E.
Peters, Lacolle
Kurtzman, Yaira
Forman, Stephen J.
Rosen, Steven
Kwak, Larry W.
Iyer, Swaminathan P.
BLOOD, 2019, 134
[37] BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T-CELL LYMPHOMA PATIENTS: A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI
Carella, M.
Pellegrini, C.
Corradini, P.
Orsucci, L.
Volpetti, S.
Argnani, L.
Dodero, A.
Stefoni, V.
Zinzani, P. L.
HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
[38] The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
Sibon, David
Khater, Sherine
Bruneau, Julie
Brouzes, Chantal
Lhermitte, Ludovic
Molina, Thierry Jo
Cartron, Guillaume
Morel, Veronique
Malamut, Georgia
Chauchet, Adrien
Morschhauser, Franck
Perard, Baptiste
Boulet, Jean-Michel
Gauchy, Anne-Cecile
Cerf-Bensussan, Nadine
Macintyre, Elizabeth A.
Asnafi, Vahid
Cellier, Christophe
Hermine, Olivier
BLOOD, 2021, 138
[39] Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi
Stefoni, Vittorio
Corradini, Paolo
Orsucci, Lorella
Volpetti, Stefano
Argnani, Lisa
Dodero, Anna
Pellegrini, Cinzia
Zinzani, Pier Luigi
BLOOD, 2020, 136
[40] Subgroup Analysis of Patients Participating in The AETHERA Trial: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
Sureda, A.
Walewski, J.
Nadamanee, A.
Masszi, T.
Agura, E.
Holowiecki, J.
Abidi, M.
Chen, A.
Stiff, P.
Viviani, S.
Carella, A.
Osmanov, D.
Bachanova, V.
Sweetenham, J.
Lee, S. -Y.
Larsen, E.
Hunder, N.
Moskowitz, H.
BONE MARROW TRANSPLANTATION, 2015, 50 : S65 - S66

← 1 2 3 4 5 →